Track topics on Twitter Track topics that are important to you
Enzo Biochem Inc. (NYSE:ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., and Enzo Life Sciences, Inc. v. Becton, Dickinson and Company, denying summary judgment that U.S. Patent No. 6,992,180 (“the ‘180 Patent”) is invalid for lack of written description, but granting summary judgment that the ‘180 Patent is invalid for lack of enablement.
The ruling addresses only one patent at issue in the ongoing patent infringement actions between Enzo and the defendants in each case. At least one other Enzo patent remains pending against each defendant in those or parallel actions. Enzo believes that the Court’s ruling was in error, and is exploring options for review of the decision.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2016. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...